David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Thursday, June 18, 2015

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate endpoint.

September 2017, Volume 3, Issue 11

August 2017, Volume 3, Issue 10

July Bonus Mid-Year Edition

July 2017, Volume 3, Issue 8

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Recent Articles

FDA Places Clinical Hold on Studies of Allogeneic CAR T-Cell Therapy

Hurricane Harvey Flooding Causes High Levels of Carcinogenic Substance

Senate Appropriations Committee Approves New Funding Bill for NIH and Opioid Crisis

Can a Post-AHCT, High-Intensity Exercise Program Improve Quality of Life in Patients With Myeloma?

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

Current Issue

September 2017, Volume 3, Issue 11

Meeting Coverage

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

Editor`s Corner

With a Little Help From My Friends

Meaningful Benefits